Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer Academic Article Article uri icon

Overview

MeSH Major

  • Adenoviridae
  • Genetic Vectors
  • Myocardial Ischemia
  • Vascular Endothelial Growth Factor A

abstract

  • Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and schedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.

publication date

  • May 1991

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00175087

PubMed ID

  • 1651908

Additional Document Info

start page

  • 187

end page

  • 90

volume

  • 9

number

  • 2